menu
    • menu
    [{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulthiame","moa":"Carbonic anhydrase","graph1":"Sleep","graph2":"Phase II","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Desitin Arzneimittel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Desitin Arzneimittel \/ Undisclosed"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"Apnimed","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Sulthiame","moa":"Carbonic anhydrase","graph1":"Sleep","graph2":"Phase II","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Desitin Arzneimittel \/ Apnimed","highestDevelopmentStatusID":"8","companyTruncated":"Desitin Arzneimittel \/ Apnimed"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"BioPharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase I","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Desitin Arzneimittel \/ BioPharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Desitin Arzneimittel \/ BioPharma Services"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"BioPharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Desitin Arzneimittel \/ BioPharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Desitin Arzneimittel \/ BioPharma Services"},{"orgOrder":0,"company":"Desitin Arzneimittel","sponsor":"BioPharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sodium Valproate","moa":"Succinate semialdehyde dehydrogenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Desitin Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Desitin Arzneimittel \/ BioPharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Desitin Arzneimittel \/ BioPharma Services"}]

    Find Clinical Drug Pipeline Developments & Deals by Desitin Arzneimittel

    Menu

    Desitin Arzneimittel

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulthiame

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Apnimed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Apnimed Acquires Global Rights to Sulthiame for Sleep and Breathing Disorders

                            Details : Through the acqusition, Apnimed will focus on clinical development of Ospolot (sulthiame), which is being evaluated in mid-stage for the treament of obstructive sleep apnea.

                            Product Name : Ospolot

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 25, 2025

                            Lead Product(s) : Sulthiame

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Apnimed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Relea...

                            Details : Sodium Valproate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Substance-Related Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2024

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.

                            Details : Sodium Valproate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2024

                            Lead Product(s) : Sodium Valproate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single-dose, Two-way Crossover Bioequivalence of Lamotrigine in Healthy Male Volunteers Under Fasting Conditio...

                            Details : Lamotrigine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 10, 2024

                            Lead Product(s) : Lamotrigine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : BioPharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed

                            Desitin Arzneimittel

                            Germany arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sulthiame

                            Therapeutic Area : Sleep

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Tolerability of Sulthiame in Patients With Obstructive Sleep Apnea (OSA)

                            Details : Sulthiame is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Sleep Apnea, Obstructive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 11, 2022

                            Lead Product(s) : Sulthiame

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth